



VFN PRAHA
VŠEOBECNÁ FAKULTNÍ
NEMOCNICE

Introduction to Paediatrics

Tomáš Honzík


Department of Paediatrics and Inherited Metabolic Disorders
First Faculty of Medicine, Charles University and General University
Hospital in Prague

Basics of Paediatric Clerkship


- demography
- screening in paediatrics
- immunization
- growth and child development
- principles of paediatric physical examination
- nutrition in childhood
- critically ill child

Demography – selected topics

The total population in the Czech Republic




Foreigners 09/2023:
1.028.441 ~ 9,5%



Živě narození, čtvrtletní data, 2018–2023

Live births, quarterly data, 2018–2023


■ 1. čtvrtletí / Q 1 ■ 2. čtvrtletí / Q 2 ■ 3. čtvrtletí / Q 3 ■ 4. čtvrtletí / Q 4




p - přeběžná data / preliminary data

| | | | | | | |
|------------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Fertility | 1,71 | 1,71 | 1,71 | 1,83 | 1,66 | 1,55 |
|------------------|-------------|-------------|-------------|-------------|-------------|-------------|


Scenario of fertility development




Evolution of natural change




Scenario of mortality development




Population by age groups




Age pyramid, Czechia, 2021



Age pyramid, Czechia, 1980



Population in the main age groups outlook



Infant mortality

1888


Infant mortality rate 330 promile

Infant mortality in the Czech Republic
1888 - 2019

Tab. 5. Průběh kojenecké úmrtnosti
v Československu a jeho zemích
v letech 1920—1947*)

| Rok | Čechy | Morava a Slezsko | Slo- vensko | Česko- slovensko |
|------|-------|------------------------|----------------|---------------------|
| 1920 | 169 | 170 | 186 | 174 |
| 1925 | 133 | 131 | 179 | 143 |
| 1930 | 124 | 118 | 161 | 135 |
| 1935 | 109 | 99 | 142 | 118 |
| 1940 | 82 | 83 | 140 | 99 |
| 1941 | 87 | 83 | 135 | 100 |
| 1942 | 90 | 89 | 160 | 111 |
| 1943 | 93 | 91 | 151 | 109 |
| 1944 | 94 | 97 | 143 | 109 |
| 1945 | 124 | 123 | 172 | 138 |
| 1946 | 93 | 96 | 146 | 109 |
| 1947 | 79 | 74 | 114 | 88 |
| 1948 | 71 | 72 | 109 | 83 |
| 1949 | 67 | | 114 | 82 |


Infant mortality rate, 1950-2019




2023

Infant mortality rate 2.5 promile

Infant mortality EU



Infant Mortality Rate by Country 2022




Infant Mortality Rate




Prematurity rate

Birth weight < 2.5kg (8.5%)




3. Struktura narozených podle porodní hmotnosti - živě narození a mrtvě narození




Birth weight < 1.5kg (2.7%)

Neonatal mortality



Neonatal mortality
According to birth weight - preterm



Immunization

Vaccination system in the Czech Republic

| Age | Routine (requested) vaccines |
|------------------|--|
| 2 <u>mo</u> | DTaP-Hib-HepB-IPV* - 1 st dose (IM) Pneumococcal conjugate (PCV13)¶ - 1 st dose (IM) <i>optional</i> |
| 4 <u>mo</u> | DTaP-Hib-HepB-IPV - 2 nd dose (IM) Pneumococcal conjugate (PCV13) - 2 nd dose (IM) <i>optional</i> |
| 11-12 <u>mos</u> | DTaP-Hib-HepB-IPV - 3 rd dose (IM) Pneumococcal conjugate (PCV13) - 3 rd dose (IM) <i>optional</i> |
| 15-18 <u>mos</u> | MMR£ - 1 st dose (SC) |
| 5-6 <u>yrs</u> | DTaP – booster dose (IM) |
| 5-6 <u>yrs</u> | MMR – booster dose (SC) |
| 10-11 <u>yrs</u> | DTaP-IPV – booster dose (IM) |
| 13-14 <u>yrs</u> | HPV* (IM) <i>optional</i> |

IM – intramuscular injection; mo/s – month(s); SC subcutaneous injection; yrs – years

*inactivated microorganisms – IPV; part of the organism – aP, HPV, HepB; polysaccharide capsule conjugated with protein carriers – Hib; toxoids – DT


¶polysaccharide capsule conjugated with protein carrier

£live-attenuated

other optional vaccines (covered by Government) – MenB, MCV

All children in the Czech Republic should be vaccinated against 13 diseases

Annual tuberculosis incidence (per 100,000 population), by region — worldwide, 2017



Vietnam 176/100,000 (2020) 296/100,000 (2000)
Ukraine 77/100,000

Passive immunization

| Product | Indications |
|---|---|
| Immune globulin intramuscular (IGIM) | Replacement therapy (antibody deficiency) Measles prophylaxis <u>HepA prophylaxis</u> |
| Immune globulin intravenous (IGIV) | PIMS-TS Kawasaki disease Varicella postexposure prophylaxis |
| <u>HepB immunoglobulin (IM)</u> <i>specific hyperimmune immunoglobulin</i> | Postexposure prophylaxis Prevention of perinatal infection |
| Rabies immunoglobulin (IM) | Postexposure prophylaxis |
| Tetanus immunoglobulin (IM) | Wound prophylaxis; treatment of tetanus |
| <u>Varicella-zoster immunoglobulin (IM)</u> | Postexposure prophylaxis |
| Palivizumab (monoclonal antibody), humanized mouse (IM) | Prophylaxis for infants against respiratory syncytial virus |

PIMS-TS – pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV2

Notes for physical examination

Pulse/respiratory rate, blood pressure

Normal resting pulse

| Age | Beats/min |
|------------|-----------|
| <1 year | 110-160 |
| 2-4 years | 95-150 |
| 5-12 years | 80-120 |
| >12 years | 60-100 |

Respiratory rate (breaths/min)

| Age | Normal | Tachypnoea |
|------------|--------|------------|
| 0-2 months | 30-50 | >60 |
| Infant | 25-40 | >50 |
| 1-5 years | 25-35 | >40 |
| 6-8 years | 20-25 | >30 |
| >8 years | 15-20 | >20 |

| Age | sBP mmHg | Upper limit |
|------------|----------|-------------|
| Newborn | 50-70 | 80 |
| Infant | 70-90 | 100 |
| 1-5 years | 80-100 | 110 |
| 6-10 years | 90-110 | 120 |



Balloon in the cuff >2/3 of the length of the upper arm